Antares Pharma (ATRS) versus Align Technology (ALGN) Head to Head Survey

Antares Pharma (NASDAQ: ATRS) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Antares Pharma and Align Technology, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Antares Pharma 0 0 3 1 3.25
Align Technology 0 1 10 0 2.91

Antares Pharma presently has a consensus price target of $3.95, suggesting a potential upside of 73.25%. Align Technology has a consensus price target of $237.64, suggesting a potential downside of 8.05%. Given Antares Pharma’s stronger consensus rating and higher probable upside, equities analysts plainly believe Antares Pharma is more favorable than Align Technology.

Valuation and Earnings

This table compares Antares Pharma and Align Technology’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Antares Pharma $52.22 million 6.84 -$24.33 million ($0.11) -20.73
Align Technology $1.08 billion 19.19 $189.68 million $3.30 78.31

Align Technology has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Antares Pharma has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.

Insider and Institutional Ownership

34.6% of Antares Pharma shares are held by institutional investors. Comparatively, 82.9% of Align Technology shares are held by institutional investors. 11.6% of Antares Pharma shares are held by insiders. Comparatively, 1.6% of Align Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Antares Pharma and Align Technology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Antares Pharma -32.06% -43.05% -24.14%
Align Technology 19.98% 25.60% 18.04%

Summary

Align Technology beats Antares Pharma on 11 of the 15 factors compared between the two stocks.

Antares Pharma Company Profile

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

Align Technology Company Profile

Align Technology, Inc. designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment. The Clear Aligner segment consists of its Invisalign System, which includes Invisalign Full, Teen and Assist (Comprehensive Products), Express/Lite (Non-Comprehensive Products) and Vivera Retainers, along with its training and ancillary products for treating malocclusion (Non-Case). The Scanner segment consists of intra-oral scanning systems and other services available with the intra-oral scanners that provide digital alternatives to the traditional cast models. The Scanner segment includes its iTero scanner and OrthoCAD services.

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply